Obes Surg. 2022 Jan 10; doi: 10.1007/s11695-021-05870-4. Epub 2022 Jan 10.

Diabetes Resolution at 10 Years After Biliopancreatic Diversion in Overweight and Class 1 Obese Patients with Type 2 Diabetes.

Obesity surgery

Francesco Saverio Papadia, Flavia Carlini, Alice Rubartelli, Micaela Battistini, Renzo Cordera, Gian Franco Adami, Giovanni Camerini

PMID: 35013895 DOI: 10.1007/s11695-021-05870-4

Abstract

BACKGROUND: Long-term anti-diabetic effects of BPD in overweight or class 1 obese T2DM patients were investigated reporting the results at 10 years after BPD performed in severely non-obese T2DM patients.

MATERIAL AND METHODS: Thirty T2DM patients with BMI lower than 35 kg/m

RESULTS: Mean levels of fasting blood glucose (FBG) and serum glycated hemoglobin (HbA1

CONCLUSION: Despite satisfactory long-term metabolic outcomes, these data indicate that BPD should be used with caution as a metabolic procedure in the treatment of T2DM in overweight or class 1obese patients.

© 2022. The Author(s).

Keywords: Biliopancreatic diversion; Long-term results; Metabolic surgery; Non-morbid obesity; Type 2 diabetes

References

1. Han Y, Jia Y, Wang H, et al. Comparative analysis of weight loss and resolution of comorbidities between laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: a systematic review and meta-analysis based on 18 studies. Int J Surg. 2020;76:101–10. - PubMed
2. Sjöholm K, Pajunen P, Jacobson P, et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia. 2015;58:1448–53. - PubMed
3. Schauer PR, Bhatt DL, Kirwan JP, et al. STAMPEDE Investigators. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med. 2017;16:376641–51. - PubMed
4. Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293–304. - PubMed
5. Sheng B, Truong K, Spitler H, et al. The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg. 2017;27:2724–32. - PubMed
6. Iaconelli A, Panunzi S, De Gaetano A, et al. Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care. 2011;34:561. - PubMed
7. Romeo S, Jacobson P, Maglio C, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2. Diabetes. 2012;35:2613. - PubMed
8. Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg. 2013;216:545–56. - PubMed
9. Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. - PubMed
10. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964. - PubMed
11. Courcoulas AP, Johnson E, Arterburn DE, et al. Reduction in long-term mortality after sleeve gastrectomy and gastric bypass compared to non-surgical patients with severe obesity. Ann Surg. 2021. https://doi.org/10.1097/SLA.0000000000005155 . - PubMed
12. Aminian A, Wilson R, Zajichek A, et al. Cardiovascular outcomes in patients with type 2 diabetes and obesity: comparison of gastric bypass, sleeve gastrectomy, and usual care. Diabetes Care. 2021;44(11):2552–63. - PubMed
13. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1576–85. - PubMed
14. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, et al. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes. 2003;52:1098–103. - PubMed
15. Briatore L, Salani B, Andraghetti G, et al. Restoration of acute insulin response n T2DM subjects 1 month after biliopancreatic diversion. Obesity (Silver Spring). 2008;16:77–81. - PubMed
16. Scopinaro N, Camerini G, Papadia F, et al. Long-term clinical and functional impact of biliopancreatic diversion on type 2 diabetes in morbidly and non-morbidly obese patients. Surg Obes Relat Dis. 2016;12:822–7. - PubMed
17. Bozkurt E, Kaya C, Ömeroğlu S, et al. The rapid effects of sleeve gastrectomy on glucose homeostasis and resolution of diabetes mellitus. Endocrinol Diabetes Metab. 2020;4:e00182. - PubMed
18. Müller-Stich BP, Senft JD, Warschkow R, et al. Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg. 2015;261:421–9. - PubMed
19. Horwitz D, Saunders JK, Ude-Welcome A, et al. Three-year followup comparing metabolic surgery versus medical weight management in patients with type 2 diabetes and BMI 30–35. Surg Obes Relat Dis. 2016;12(7):1337–41. - PubMed
20. Cummings DE, Cohen RV. Bariatric/metabolic surgery to treat type 2 diabetes in patients with a BMI <35 kg/m2. Diabetes Care. 2016;39:924–33. - PubMed
21. Di J, Zhang H, Yu H, et al. Effect of Roux-en-Y gastric bypass on the remission of type 2 diabetes: a 3-year study in Chinese patients with a BMI <30 kg/m2. Surg Obes Relat Dis. 2016;12:1357–63. - PubMed
22. Scopinaro N, Adami GF, Bruzzi P, et al. Prediction of diabetes remission at long term following biliopancreatic diversion. Obes Surg. 2017;27:1705–8. - PubMed
23. Adami GF, Camerini G, Papadia F, et al. Type 2 diabetes remission and control in overweight and in mildly obese diabetic patients at long-term follow-up after biliopancreatic diversion. Obes Surg. 2019;29:239–45. - PubMed
24. Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopancreatic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg. 2011;253:699–703. - PubMed
25. Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22(936):46. - PubMed
26. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5. - PubMed
27. Huang CK, Shabbir A, Lo CH, et al. Laparoscopic Roux-en-Y gastric bypass for the treatment of type II diabetes mellitus in Chinese patients with body mass index of 25–35. Obes Surg. 2011;21:1344–9. - PubMed
28. Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes in obese individuals. Diabetologia. 2018;61:257–64. - PubMed
29. Wu D, Wang L, Jiang T. Efficacy comparison of laparoscopic sleeve gastrectomy in type 2 diabetes patients with a BMI 30–34.9 kg/m - PubMed
30. Lee WJ, Almulaifi A, Chong K, et al. The effect and predictive score of gastric bypass and sleeve gastrectomy on type 2 diabetes mellitus patients with BMI < 30 kg/m/2. Obes Surg. 2005;25:1772–8. - PubMed
31. Vigneshwaran B, Wahal A, Aggarwal S, et al. Impact of sleeve gastrectomy on type 2 diabetes mellitus, gastric emptying time, glucagon-like peptide 1 (GLP-1), ghrelin and leptin in non-morbidly obese subjects with BMI 30–35.0 kg/m - PubMed
32. Camerini GB, Papadia FS, Carlini F, et al. The long-term impact of biliopancreatic diversion on glycemic control in the severely obese with type 2 diabetes mellitus in relation to preoperative duration of diabetes. Surg Obes Relat Dis. 2016;12:345–9. - PubMed
33. Moriconi D, Manca ML, Anselmino M, et al. Predictors of type 2 diabetes relapse after Roux-en-Y Gastric Bypass: a ten-year follow-up study. Diabetes Metab. 2021;48(1):101282. - PubMed
34. Kapeluto JE, Tchernof A, Masckauchan D, et al. Ten-year remission rates in insulin-treated type 2 diabetes after biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2020;16:1701–12. - PubMed
35. Bolckmans R, Himpens J. Long-term (>10 Yrs) Outcome of the laparoscopic biliopancreatic diversion with duodenal switch. Ann Surg. 2016;264:1029–37. - PubMed
36. llenbroek JH, Töns HAM, Hanegraaf MAJ, et al. Pancreatic α-cell mass in obesity. Diabetes Obes Metab. 2017;19:1810–3. - PubMed
37. Saisho Y, Butler AE, Manesso E, et al. β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care. 2013;36:111–7. - PubMed
38. Papadia F, Carlini F, Rubartelli A, et al. Insulin action in subjects with type 2 diabetes following biliopancreatic diversion. Eur J Clin Invest. 2021;12:e13727. - PubMed
39. Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005;28:2406–11. - PubMed

Publication Types

• Journal Article